Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Preclinical rare cancer research to inform clinical trial design

With improved biobanking of rare cancer tissue enabling more in-depth tumour profiling, as well as generation of clinically relevant rare cancer preclinical models, treatment strategies for patients with rare cancer will rapidly advance. The future successes of rare cancer research, with alternative approaches for diagnosing, researching and conducting clinical trials, will ultimately benefit patients with all types of cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 18, 1022–1039 (2017).

    Article  Google Scholar 

  2. Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744–750 (2019).

    Article  CAS  Google Scholar 

  3. Puca, L. et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 9, 2404 (2018).

    Article  Google Scholar 

  4. Phan, N. et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun. Biol. 2, 78 (2019).

    Article  Google Scholar 

  5. Ray-Coquard, I., Pujade-Lauraine, E. & Ledermann, J. A. New clinical research strategies for rare gynecologic malignancies. Curr. Opin. Obstet. Gynecol. 27, 53–57 (2015).

    Article  Google Scholar 

  6. Nunn, J. S. et al. in Textbook of Uncommon Cancers 5th edn (eds Raghavan, D. et al.) 12–18 (Wiley, 2017).

Download references


This work was supported by fellowships from the Stafford Fox Medical Research Foundation (C.L.S. and H.E.B.); Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to C.L.S.); the Victorian Cancer Agency (Clinical Fellowships CRF10-20 and CRF16014 to C.L.S.). This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Medical Research Institutes Infrastructure Support Scheme.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Clare L. Scott.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

International Rare Cancers Initiative:

Supplementary Information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Barker, H.E., Scott, C.L. Preclinical rare cancer research to inform clinical trial design. Nat Rev Cancer 19, 481–482 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer